Transcat (NASDAQ:TRNS) Rating Reiterated by Oppenheimer

Transcat (NASDAQ:TRNS)‘s stock had its “outperform” rating reiterated by Oppenheimer in a note issued to investors on Thursday, Benzinga reports. They currently have a $125.00 target price on the scientific and technical instruments company’s stock, up from their prior target price of $120.00. Oppenheimer’s target price points to a potential upside of 19.38% from the company’s current price.

Several other analysts also recently commented on TRNS. TheStreet raised shares of Transcat from a “c+” rating to a “b” rating in a research report on Wednesday, January 31st. HC Wainwright reissued a “buy” rating and issued a $124.00 target price on shares of Transcat in a research report on Tuesday.

Transcat Stock Down 3.5 %

Transcat stock opened at $104.71 on Thursday. The firm has a market cap of $924.59 million, a PE ratio of 80.55 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.81 and a current ratio of 3.37. The firm’s 50 day moving average price is $108.70 and its two-hundred day moving average price is $101.88. Transcat has a twelve month low of $74.89 and a twelve month high of $115.41.

Transcat (NASDAQ:TRNS) last posted its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.35 by $0.03. The company had revenue of $65.17 million during the quarter, compared to the consensus estimate of $63.36 million. Transcat had a net margin of 4.16% and a return on equity of 9.32%. On average, research analysts predict that Transcat will post 1.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Lee D. Rudow sold 5,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the sale, the chief executive officer now directly owns 108,478 shares of the company’s stock, valued at approximately $12,073,601.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Transcat news, CEO Lee D. Rudow sold 5,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the completion of the sale, the chief executive officer now directly owns 108,478 shares of the company’s stock, valued at approximately $12,073,601.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Charles P. Hadeed sold 700 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $113.00, for a total transaction of $79,100.00. Following the completion of the sale, the director now directly owns 22,678 shares of the company’s stock, valued at $2,562,614. The disclosure for this sale can be found here. In the last three months, insiders sold 8,073 shares of company stock valued at $900,023. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Transcat

A number of hedge funds have recently made changes to their positions in TRNS. Wasatch Advisors LP raised its stake in shares of Transcat by 13.3% in the 4th quarter. Wasatch Advisors LP now owns 701,099 shares of the scientific and technical instruments company’s stock valued at $76,651,000 after buying an additional 82,458 shares in the last quarter. Broadcrest Asset Management LLC raised its stake in shares of Transcat by 17.6% in the 4th quarter. Broadcrest Asset Management LLC now owns 400,000 shares of the scientific and technical instruments company’s stock valued at $43,732,000 after buying an additional 60,000 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Transcat by 184.9% in the 1st quarter. Bank of America Corp DE now owns 83,687 shares of the scientific and technical instruments company’s stock valued at $6,790,000 after buying an additional 54,314 shares in the last quarter. Comerica Bank acquired a new position in shares of Transcat in the 3rd quarter valued at $5,221,000. Finally, Vanguard Group Inc. raised its stake in shares of Transcat by 12.3% in the 4th quarter. Vanguard Group Inc. now owns 477,799 shares of the scientific and technical instruments company’s stock valued at $52,238,000 after buying an additional 52,421 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.